Table 1.

Disease-modifying therapies: indications and dosing

Therapies	Indications	Dosing
Rituximab	SS, SLE, RA, AAV, IgG-4 RD	Induction: 1 g IV days 1 and 15 Maintenance: 1 g IV q6mo
Cyclophosphamide	SS, SLE, RA, NS, AAV, NBD	500–1000 mg IV monthly for 3–6 months
Azathioprine	SLE, NBD, NS, AAV, IgG4-RD,	Starting dose: 50 mg/day PO or SQ bid Goal titration: 2–3 mg/kg/day PO
Methotrexate	RA, NS, AAV, IgG4-RD	12–25 mg PO or IV q1wk For AAV—0.3 mg/kg/day PO
Mycophenolate Mofetil	NBD, NS, AAV, IgG4-RD	750–1500 mg PO bid
Infliximab	NBD, NS, ADA2 associated vasculitis	Most indications—starting dose is 5 mg/kg IV For RA—starting dose is 3 mg/kg/day IV Induction: 0, 2, 6 wk. Maintenance: q8wk *Dose can be increase to 8–10 mg/kg and maintenance interval can be decreased as needed to q6wk
Adalimumab	NS, NBD	40 mg SQ q2wk
Tocilizumab	NBD	8 mg/kg IV q4wk
Abatacept	RA, CTLA-4 related infiltrative disease	SQ dosing Induction: - Day 1: 125 mg SQ + 10 mg/kg IV - Day 8: 125 mg SQ Maintenance: 125 mg SQ q1wk IV dosing Induction: 10 mg/kg IV on days 1, 15, 29 Maintenance: 10 mg/kg IV q4wk
Natalizumab	ICI associated AE	300 mg IV q4wk
Immunoglobulin	SLE, CVID-associated granulomatous disease	2 g/kg IV divided over 3–5 days (0.4–0.66 g/kg/day)
Hydroxychloroquine	SLE	5 mg/kg/day PO

AAV ANCA-associated vasculitis, ADA2 adenosine deaminase 2, AE autoimmune encephalitis, CTLA-4 cytotoxic T lymphocyte antigen-4, CVID common variable immunodeficiency, ICI immune checkpoint inhibitor, IgG-4 RD IgG4-related disease, NBD Neuro-Behcet’s disease, NS neurosarcoidosis, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SS Sjogren’s syndrome